Aug. 21 at 10:06 PM
$AQST Aquestiveâs âseeing is believingâ preference surveys tested real-world carry preference by mailing physical mock-ups of an auto-injector, nasal spray, and the Anaphylm film to patients and caregivers (including parents of at-risk children).
In one double-blinded study (n=35: 17 adult patients + 18 pediatric caregivers), respondents opened sealed packages containing unlabeled demo devices during video interviews and were told to assume equal efficacy, safety, HCP endorsement, and cost. The large majority preferred the film.
In a related/expanded version (~52â53 participants), nearly everyone chose the film; only one preferred the nasal spray and one rated film and nasal equally.
These results highlight Anaphylmâs non-device size that fits in a wallet or phone case, making it a never-forget, life-saving, best-in-class innovation that patients and caregivers strongly favor for everyday portability over bulkier alternatives.
